Looking for a specific product?

Make a search for products & suppliers, articles & news.

Pronova BioPharma launches Consumer Healthcare business

Pronova BioPharma ASA today announced plans to expand into the consumer healthcare market, enabling the company to further leverage the company's position as the world's largest manufacturer of highest grade omega-3 derived products.

Pronova BioPharma will develop its business in the omega-3 consumer healthcare market over the next year, initially targeting the high concentrate dietary supplement market, which is expected to double in size over the next five years (source: GOED and Pronova estimates).

 

The development of the Consumer Healthcare business will offer substantial synergies with Pronova BioPharma's existing pharmaceutical business, which manufactures the highly successful Omacor/Lovaza drug. The first and only FDA and EU approved omega-3 derived pharmaceutical drug, Omacor/Lovaza has achieved blockbuster status and is sold in 57 countries. Pronova BioPharma is also developing a promising pipeline of prescription-only pharmaceutical products, including PRC-4016 which is currently in clinical trials for the treatment of combined dyslipidemia.

 

Pronova BioPharma has invested USD 500 million in recent years in creating world-leading, large capacity and high concentrate omega-3 manufacturing facilities in Norway and Denmark. The company is already the world's leading manufacturer and supplier of omega-3-derived active pharmaceutical ingredients. Consequently, the initial investment necessary to establish a Consumer Healthcare business is relatively small, and is estimated at USD 10 million over the next 12 months, which will be used to adjust the manufacturing process to the consumer health market.

 

The company will leverage its significant partnership experience to seek appropriate partners to market and sell its consumer products around the world and ensure rapid take-up and penetration.

 

The strong body of clinical data that has driven the success of Omacor/Lovaza has greatly increased awareness of the overall benefits of high grade omega-3 pharmaceuticals and supplements, which have been demonstrated to have a beneficial impact in a wide range of therapeutic areas, including cardiovascular health and metabolic conditions.

 

Use of omega-3 supplements is growing rapidly worldwide, with almost one in four people reporting use of an omega-3 product in the USA, up 64 percent from just five years ago (source: imn). The board of Pronova BioPharma believes the potential for continued growth of differentiated, high quality omega-3 supplements supported by clinical data is significant as awareness of their health benefits continues to expand in both developed and emerging markets.

Pronova BioPharma plans to enter the consumer healthcare market during the second half of 2012. The company will spend the next 12 months building the Consumer Healthcare organisation, adjusting the manufacturing processes for consumer products, initiating small clinical trials and developing distribution channels.

Morten Jurs, CEO of Pronova BioPharma, commented, "The combination of aging populations, changing lifestyles and the increasing awareness of the importance of omega-3 in maintaining good health are expected to drive strong growth in both pharmaceutical grade and high quality consumer-focused omega-3 products in the coming years."

"This new division will be highly complementary to Pronova BioPharma's existing pharmaceutical business, in which we have invested heavily in recent years to create the best manufacturing facilities and processes in the world and to develop a pipeline of promising new drugs. Having established a dominant position in the omega-3 pharmaceutical market, we are well positioned to leverage our existing infrastructure, knowledge, research, regulatory and partnership capabilities in order to drive a highly successful consumer business targeting a different segment of the population."

Related news

Latest news

Eimskip strengthens its worldwide forwarding services by acquiring the logistics company SHIP-LOG A/S in Denmark

Eimskip has strengthened its position in worldwide logistics services by acquiring 75% of the freight forwarding company SHIP-LOG. 

For Sale Assets from the former BMV LAKSEVÄG YARD in Bergen, Norway!

For Sale Assets from the former BMV LAKSEVÄG YARD in Bergen, Norway! The entire shipbuilding and fabricating facility is closing and more than 500 lots is on sale.

Servogear CPP for Seasight II - Future of the Fjords

We are proud to announce that Servogear has been chosen for the delivery of Servogear...

TechnipFMC Signs Agreement with Pall to Supply Slurry Oil Filtration Systems for Fluid Catalytic Cracking Units

The associated activities will be managed by TechnipFMC Process Technology’s center in Houston,

10 Million kroner for verification funding

The Norwegian Research Council has granted 10 million...

Hilti acquires Oglaend System Group

Oglaend System’s headquarters will remain in Klepp, 

DOF Subsea AS ("DOF Subsea" or the "Company") today announces its intention to launch an initial public offering (the "IPO") of its ordinary shares and to apply for a listing on Oslo Børs

NOT FOR DISTRIBUTION OR RELEASE,

DOF Subsea North America extends charter for Jones Act Compliant vessel Harvey Deep Sea

The Harvey Deep Sea Vessel is a Multi-Purpose DPII Construction,

Untrue rumours about an on-going incident at the Halden Research Reactor in Norway

The Norwegian Radiation Protection Authority has become aware that stories about an ongoing incident involving a “meltdown” at the Norwegian Institute for Energy Technology (IFE) reactor situated in Halden are currently ci...